D047428Chemicals & DrugsD27.505.519.389.75550730.956707Protein Kinase InhibitorsFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonCancer BiologyDermatologyWake Forest School of MedicineWilliamGmeinerWilliam H. Gmeiner PhD36.09032400000000-80.2664910000000080Gmeiner, WilliamProfessorStevenFeldmanSteven R. Feldman MD, PhD36.08959100000000-80.26859900000000884Feldman, StevenProfessorCaio MaxRocha LimaCaio Max S. Rocha Lima MD, MS2211Rocha Lima, Caio MaxProfessor20Professor31365783Chen Z, Shao T, Gao W, Fu H, Collier TL, Rong J, Deng X, Yu Q, Zhang X, Davenport AT, Daunais JB, Wey HY, Shao Y, Josephson L, Qiu WW, Liang SChemMedChemChen Z, Shao T, Gao W, Fu H, Collier TL, Rong J, Deng X, Yu Q, Zhang X, Davenport AT, Daunais JB, Wey HY, Shao Y, Josephson L, Qiu WW, Liang S. Synthesis and Preliminary Evaluation of [11 C]GNE-1023 as a Potent PET Probe for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson's Disease. ChemMedChem. 2019 09 04; 14(17):1580-1585.ChemMedChem2019-08-22T00:00:002019Synthesis and Preliminary Evaluation of [11 C]GNE-1023 as a Potent PET Probe for Imaging Leucine-Rich Repeat Kinase 2 (LRRK2) in Parkinson's Disease.Internal Medicine, Hematology & OncologyInternal Medicine, Molecular MedicineStevenParkSteven Park MD3224Park, StevenClinical Professor32338136Reed DR, Sen JM, Pierce EJ, Elsarrag RZ, K Keng MJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy PractitionersReed DR, Sen JM, Pierce EJ, Elsarrag RZ, K Keng M. Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients. J Oncol Pharm Pract. 2020 Jul; 26(5):1200-1212.J Oncol Pharm Pract2020-04-26T00:00:002020Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.30992232Reed DR, Hall RD, Gentzler RD, Volodin L, Douvas MG, Portell CAClinical lymphoma, myeloma & leukemiaReed DR, Hall RD, Gentzler RD, Volodin L, Douvas MG, Portell CA. Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):e247-e250.Clin Lymphoma Myeloma Leuk2019-03-11T00:00:002019Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.JingyunLeeJingyun Lee PhD3545Lee, JingyunAssistant Professorhttps://wfbmc.ilabsolutions.com/service_center/3917Proteomics and Metabolomics Shared Resource (PMSR)31827241Phillips DC, Jin S, Gregory GP, Zhang Q, Xue J, Zhao X, Chen J, Tong Y, Zhang H, Smith M, Tahir SK, Clark RF, Penning TD, Devlin JR, Shortt J, Hsi ED, Albert DH, Konopleva M, Johnstone RW, Leverson JD, Souers AJLeukemiaPhillips DC, Jin S, Gregory GP, Zhang Q, Xue J, Zhao X, Chen J, Tong Y, Zhang H, Smith M, Tahir SK, Clark RF, Penning TD, Devlin JR, Shortt J, Hsi ED, Albert DH, Konopleva M, Johnstone RW, Leverson JD, Souers AJ. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. Leukemia. 2020 Jun; 34(6):1646-1657.Leukemia2019-12-11T00:00:002019A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies.32270047Au KM, Wang AZ, Park SIScience advancesAu KM, Wang AZ, Park SI. Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma. Sci Adv. 2020 Apr; 6(14):eaaz9798.Sci Adv2020-04-01T00:00:002020Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma.true1ProfessorProfessortrue1ProfessorProfessortrue1Clinical ProfessorClinical Professortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professor1.058840.018303750research area of0.7661010.022489593subject area for